Table of Contents
Big Pharma has begun investing in regenerative medicine: Genzyme in 2008, Pfizer and Novartis in 2009, and Cephalon in 2010. In 3-5 years, investment will reach a “tipping point”, after which no medical industry players will want to be left behind. This report covers the development of therapies to replace human cells or promote their regeneration: including cell therapies, tissue engineering, drugs, and medical devices. Each company p...More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Shadi
+1 718 618 4897
This report analyzes the worldwide markets for Mesenchymal Stem Cells (MSCs) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest ...
Mice Model Market - by Type [Inbred, Knockout, Conditioned], Technology [Microinjection, Embryonic Stem Cell], Disease [Oncology, Immunology, CNS], Service [Breeding, Cryopreservation, Quarantine] & Care ...
Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective ...
... Approvals were obtained prior to study initiation ziebe et al. 2013 In press, fertility & sterility design demonstrate that addition of 2 ng/ml gm-csf to the control medium would increase the ongoing ...
Reportlinker.com © Copyright 2014. All rights reserved.